Navigation Links
ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

MOUNTAIN VIEW, Calif., Jan. 6, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at J.P. Morgan's 29th Annual Healthcare Conference on Wednesday, January 12, 2011, at 10:00 a.m. Pacific at the Westin St. Francis Hotel in San Francisco, CA.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. Phase III clinical trials of Traficet-EN are expected to initiate in the first quarter 2011. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in Phase I clinical development. ChemoC
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
2. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
3. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
4. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
8. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
9. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary ... year ended March 31, 2015. Based on ... March 31, 2015, Organovo estimates: , Total ... and approximately $571 thousand for the fiscal year , ... and fiscal year ended March 31, 2015 of approximately ...
(Date:4/21/2015)... --Algae International Group, Inc. ( ALGA ), through its ... exceptional Hempster T-Shirt sales following yesterday,s online sales launch. ... introduced four t-shirt designs specific to the ,Hempster Clothing, ... the online sales of these first four t-shirts over ... to the  Marijuana Policy Project  (MPP), an organization dedicated ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
Breaking Medicine Technology:Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 2Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 3Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 4American Seed & Oil Company 420 Hempster T-Shirt Sales Soar; Online Sales Launched Yesterday with Start of 420 Week; Over 2000 Shirts Sold So Far 2World Caps & Closures Market 2World Caps & Closures Market 3
(Date:4/21/2015)... Displays & Exhibits, Inc. a division of Absolute ... building industry, announced a management change of the retail ... in Tustin, California.“It is very important to have a ... in quality as offered by overseas trade show accessories ... Adduru is the new manager of Displays & Exhibits ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in California’s ... to automatically send continuation of care documents (CCDs). When ... communication with clinics and other ambulatory practices, they selected ... , “Provider Alert will enable the physician offices ... need to provide continuing care in real time,” said ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... 21, 2015 The report ... comparative analysis on the therapeutic development for ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
(Date:4/21/2015)... Information is the best weapon in the fight for your ... their families with knowledge about living with cancer in his ... Answer" and new website . , In the book, ... diagnosis through treatment and even death. The goal, he says, ... home and in the examination room. , “Cancer patients and ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2
... The following is being issued by Cheryl ... 721 will streamline the health care process for ... long waits and associated, unnecessary costs because they ... treatment."Currently, patients seeking rehabilitation for functional impairments due ...
... experts say, , , THURSDAY, March 5 (HealthDay News) -- Men ... life span by more than two years, Swedish researchers say. ... beneficial effect on length of life as quitting smoking in ... exercise, the researchers said. But Dr. Karl Michaëlsson, a senior ...
... Group, Inc. (OTC Bulletin Board: POLGA ; OTC ... marketer of engineered materials, announced today it will release ... of the market on Wednesday, March 18, 2009. Company ... slides, starting at 10:00 a.m. EDT on Thursday, March ...
... March 5 Despite dermatologists, continual efforts, ... harmful effects of excessive sun exposure and regular use ... to reduce the risk of developing skin cancer. But ... may help encourage them to apply sunscreen regularly via ...
... BRIARCLIFF MANOR, N.Y., March 5 SETO Holdings, Inc. (Pink ... under which it agreed in principle (1) to issue shares ... stock of Advanced Hearing Centers, Inc. ("AHC"), a Maryland corporation ... locations in Maryland and one in Virginia, and (2) to ...
... of infection, study says , , THURSDAY, March 5 (HealthDay News) ... existing vaccines so that they can protect people during a ... ,killer T-cell, is the hit-man of the immune system. It ... body, helping rid us of infections," the study,s lead author, ...
Cached Medicine News:Health News:Men Who Get Active in Midlife Live Longer 2Health News:Men Who Get Active in Midlife Live Longer 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 3Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 4Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established....
Used to introduce balloon, electrode, closed or non-tapered end and other catheters....
Medicine Products: